Patents by Inventor Rahul Rajan Kaushik

Rahul Rajan Kaushik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TNF ALPHA ANTIBODY FORMULATIONS
    Publication number: 20230151086
    Abstract: Stable adalimumab formulations are disclosed.
    Type: Application
    Filed: August 19, 2022
    Publication date: May 18, 2023
    Applicant: Amgen Inc.
    Inventors: William J. CALLAHAN, Rahul Rajan KAUSHIK, Joy BRENNAN
  • VEGFR-FC FUSION PROTEIN FORMULATIONS
    Publication number: 20230025418
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 14, 2022
    Publication date: January 26, 2023
    Applicant: Amgen Inc.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • Reduced viscosity protein pharmaceutical formulations
    Patent number: 11459401
    Abstract: Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 4, 2022
    Assignee: Amgen Inc.
    Inventors: Alona Teran, Qahera Munaim, Nazer Khalaf, Rahul Rajan Kaushik, Christi L. Clogston, Twinkle R. Christian, William J. Callahan
  • FORMULATIONS COMPRISING A TRIS BUFFER AND A PROTEIN
    Publication number: 20210353713
    Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept. In some embodiments, the formulation comprises a Tris buffer.
    Type: Application
    Filed: October 25, 2019
    Publication date: November 18, 2021
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Rahul Rajan KAUSHIK
  • VEGFR-FC FUSION PROTEIN FORMULATIONS
    Publication number: 20200338164
    Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.
    Type: Application
    Filed: November 16, 2018
    Publication date: October 29, 2020
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, William J. CALLAHAN, Robert Matthew FESINMEYER, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • VEGFR-FC FUSION PROTEIN FORMULATIONS
    Publication number: 20200255496
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEG-FR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 17, 2018
    Publication date: August 13, 2020
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • ANTI-TNF ALPHA ANTIBODY FORMULATIONS
    Publication number: 20200087390
    Abstract: Stable adalimumab formulations are disclosed.
    Type: Application
    Filed: December 20, 2017
    Publication date: March 19, 2020
    Applicant: AMGEN INC.
    Inventors: William J. CALLAHAN, Rahul Rajan KAUSHIK, Joy BRENNAN
  • REDUCED VISCOSITY PROTEIN PHARMACEUTICAL FORMULATIONS
    Publication number: 20200024363
    Abstract: Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.
    Type: Application
    Filed: October 6, 2017
    Publication date: January 23, 2020
    Inventors: Alona Teran, Qahera Muniam, Nazer Khalaf, Rahul Rajan Kaushik, Christi L. Clogston, Twinkle R. Christian, William J. Callahan